CD274 and gastric cancer: Chemo-refractory GC patients who were TMB-H and PD-L1 positive showed long-term benefits of toripalimab with respect to ORR (33.3% vs 3.0%), PFS (2.7 vs 1.9 months), and OS (12.1 vs 4 months) compared with those with TMB-L and PD-L1 negative status (5).